Clinical Trial Update: A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing sunitinib to placebo for advanced pancreatic islet cell tumors was terminated. Results were posted in October 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Islet Cell, Carcinoma, Pancreas | Phase 3 | Status: TERMINATED | Results posted: 2010-10-11